CoChat
Sign Up
Cited by 11

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives

Jamadade, Pratiksha, Nupur, Neh, Maharana, Krushna Ch, Singh, Sanjiv·2024·Current Atherosclerosis Reports
DOI 10.1007/s11883-024-01228-0
Open this paper in CoChat — free account

Abstract

Purpose of review Globally, the prevalence of metabolic disorders is rising. Elevated low-density lipoprotein (LDL) cholesterol is a hallmark of familial hypercholesterolemia, one of the most prevalent hereditary metabolic disorders and another one is Diabetes mellitus (DM) that is more common globally, characterised by hyperglycemia with low insulin-directed glucose by target cells. It is still known that low-density lipoprotein cholesterol (LDL-C) increases the risk of cardiovascular disease (CVD). LDL-C levels are thought to be the main therapeutic objectives. Recent findings The primary therapy for individuals with elevated cholesterol levels is the use of statins and other lipid lowering drugs like ezetimibe for hypercholesterolemia. Even after taking statin medication to the maximum extent possible, some individuals still have a sizable residual cardiovascular risk. To overcome this proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors-monoclonal antibodies (mAbs) are a novel class of systemic macromolecules that have enhanced LDL-C-lowering efficacy. Along with this other inhibitor are used like Angiopoeitin like 3 inhibitors. Research on both humans and animals has shown that anti-CD3 antibodies can correct autoimmune disorders like diabetes mellitus. Individuals diagnosed with familial hypercholesterolemia (FH) may need additional treatment options beyond statins, especially when facing challenges such as statin tolerance or the inability of even the highe…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-024-01228-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 116

  1. Clemente-Suárez VJ, Mielgo-Ayuso J, Martín-Rodríguez A, Ramos-Campo DJ, Redondo-Flórez L, Tornero-Aguilera JF. The burden of carbohydrates in health and disease. Nutrients. 2022;14(18):3809. · DOI
  2. Clarke JTR. A clinical guide to inherited metabolic diseases. Cambridge University Press; 2005. · DOI
  3. Saudubray JM, Sedel F, Walter JH. Clinical approach to treatable inborn metabolic diseases: an introduction. Journal of inherited metabolic disease 2006;29(2–3):261–274. · DOI
  4. Agana M, Frueh J, Kamboj M, Patel DR, Kanungo S. Common metabolic disorder (inborn errors of metabolism) concerns in primary care practice. Ann Transl Med. 2018;6(24):469. · DOI
  5. Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol. 2019;26(2_suppl):7–14. · DOI
  6. Akkol EK, Aschner M. Chapter 1 - An overview on metabolic disorders and current therapy. In: Khan H, Akkol EK, Daglia M, editors. The role of phytonutrients in metabolic disorders. Academic Press; 2022. pp. 3–33. · DOI
  7. Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150–61. · DOI
  8. Sprangers B, Van der Schueren B, Gillard P, Mathieu C. Otelixizumab in the treatment of type 1 diabetes mellitus. Immunotherapy. 2011;3(11):1303–16. · DOI
  9. Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol Rev. 2019;14(1):50. · DOI · Paper page
  10. Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H, Martin C. Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci. 2018;19(11):3426. · DOI
  11. Vallejo-Vaz AJ, Akram A, Seshasai SRK, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial hypercholesterolaemia studies collaboration. Atheroscler Suppl. 2016;22:1–32. · DOI
  12. Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93. · DOI
  13. Xie L, Li X. Editorial: roles and mechanisms of adipokines in metabolic diseases. Front Endocrinol. 2023;14:1303966. · DOI
  14. Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23(2):786. · DOI · Paper page
  15. Haas JT, Biddinger SB. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):206. · DOI
  16. Garg A, Fazio S, Duell PB, et al. Molecular characterization of familial hypercholesterolemia in a North American cohort. J Endocr Soc. 2020;4(1):bvz015. · DOI
  17. Seidah NG, Abifadel M, Prost S, Boileau C, Prat A. The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin/kexin 9. Pharmacol Rev. 2017;69(1):33–52. · DOI · Paper page
  18. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279(47):48865–75. · DOI · Paper page
  19. Ahamad S, Bhat SA. Recent update on the development of PCSK9 inhibitors for hypercholesterolemia treatment. J Med Chem. 2022;65(23):15513–39. · DOI
  20. Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci. 2007;104(37):14604–9. · DOI
  21. Norata GD, Tibolla G, Catapano AL. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vascul Pharmacol. 2014;62(2):103–11. · DOI
  22. Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: the role of PCSK9. Arch Biochem Biophys. 2017;625:39–53. · DOI
  23. Qian Y-W, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res. 2007;48(7):1488–98. · DOI · Paper page
  24. Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci. 2009;106(24):9546-9547. · DOI
  25. Schlüter K-D, Wolf A, Schreckenberg R. Coming back to physiology: extra hepatic functions of proprotein convertase subtilisin/kexin type 9. Front Physiol. 2020;11:598649. · DOI
  26. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113–20. · DOI · Paper page
  27. Kersten S. ANGPTL3 as therapeutic target. Curr Opin Lipidol. 2021;32(6):335. · DOI
  28. Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2023;30(1):131–42. · DOI
  29. Krzemińska J, Młynarska E, Radzioch E, Wronka M, Rysz J, Franczyk B. Management of familial hypercholesterolemia with special emphasis on evinacumab. Biomedicines. 2022;10(12):3273. · DOI
  30. Akoumianakis I, Zvintzou E, Kypreos K, Filippatos TD. ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets. Curr Atheroscler Rep. 2021;23:1–11. · DOI
  31. Raschi E, Casula M, Cicero AFG, Corsini A, Borghi C, Catapano A. Beyond statins: new pharmacological targets to decrease LDL-cholesterol and cardiovascular events. Pharmacol Ther. 2023;250:108507. · DOI
  32. Kosmas CE, Bousvarou MD, Sourlas A, et al. Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia. Clin Pharmacol : Adv Appl. 2022;14:49–59. · DOI
  33. Packard CJ, Boren J, Taskinen M-R. Causes and consequences of hypertriglyceridemia. Front Endocrinol. 2020;11:252. · DOI · Paper page
  34. Lang W, Frishman WH. Angiopoietin-like 3 protein inhibition: a new frontier in lipid-lowering treatment. Cardiol Rev. 2019;27(4):211–7. · DOI
  35. Deng H, Niu Z, Zhang Z, et al. Back on the scene: advances and challenges in CD3-related drugs in tumor therapy. Drug Discovery Today. 2022;27(8):2199–208. · DOI
  36. Sigalov A, Aivazian D, Stern L. Homooligomerization of the cytoplasmic domain of the T cell receptor ζ chain and of other proteins containing the immunoreceptor tyrosine-based activation motif. Biochemistry. 2004;43(7):2049–61. · DOI
  37. Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7(1):52–64. · DOI
  38. Ashraf MT, Ahmed Rizvi SH, Kashif MAB, Shakeel Khan MK, Ahmed SH, Asghar MS. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: a systematic review, meta-analyses and meta-regression. Diabetes Obes Metab. 2023;25(11):3377–89. · DOI
  39. Jung ST, Kang TH, Kelton W, Georgiou G. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr Opin Biotechnol. 2011;22(6):858–67. · DOI
  40. Maurice Morillon Y, Martin A, Gojanovich G, Wang B, Tisch R. Reestablishing T cell tolerance by antibody-based therapy in type 1 diabetes. Arch Immunol Ther Exp. 2015;63:239–50. · DOI
  41. Manniello M, Pisano M. Alirocumab (Praluent): first in the new class of PCSK9 inhibitors. Pharm Ther. 2016;41(1):28.
  42. Parham JS, Goldberg AC. Review of recent clinical trials and their impact on the treatment of hypercholesterolemia. Prog Cardiovasc Dis. 2022;75:90–96. · DOI
  43. Bergeron N, Phan BAP, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648–66. · DOI · Paper page
  44. Hummelgaard S, Vilstrup JP, Gustafsen C, Glerup S, Weyer K. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249:108480. · DOI · Paper page
  45. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155–65. · DOI · Paper page
  46. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99. · DOI · Paper page
  47. Santos RD, Wiegman A, Caprio S, et al. Alirocumab in pediatric patients With heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA pediatr. 2024;178(3):283–293. · DOI
  48. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–82. · DOI · Paper page
  49. Okere AN, Serra C. Evaluation of the potential role of alirocumab in the management of hypercholesterolemia in patients with high-risk cardiovascular disease. Pharmacother: J Human Pharmacol Drug Ther. 2015;35(8):771–9. · DOI
  50. Zhang X-L, Zhu Q-Q, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:1–19. · DOI · Paper page
  51. Sindi AAA. Genetics, safety, cost-effectiveness, and accessibility of injectable lipid-lowering agents: a narrative review. J Lipids 2023;2023:2025490. · DOI
  52. Manso T, Kushwaha A, Abdollahi N, Duroux P, Giudicelli V, Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol. 2023;14:1129323. · DOI
  53. Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial. J Am Coll Cardiol. 2020;76(2):131–42. · DOI
  54. Singh SK, Mahler H-C, Hartman C, Stark CA. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants? J Pharm Sci. 2018;107(11):2735–41. · DOI
  55. Sinnaeve PR, Schwartz GG, Wojdyla DM, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41(24):2248–58. · DOI
  56. Pérez de Isla L, Díaz-Díaz JL, Romero MJ, et al. Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study. Circulation. 2023;147(19):1436–43. · DOI
  57. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol. 2017;9(2):76. · DOI · Paper page
  58. Iannuzzo G, Buonaiuto A, Calcaterra I, et al. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: a single center real-world study. Nutr Metab Cardiovasc Dis. 2022;32(3):684–91. · DOI
  59. Wallemacq C. Evolocumab (Repatha®): a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy. Rev Med Liege. 2017;72(11):505–12.
  60. Luthra G, Shahbaz M, Almatooq H, et al. Exploring the efficacy of alirocumab and evolocumab in reducing low-density lipoprotein (LDL) cholesterol levels in patients with familial hypercholesterolemia: a systematic review. Cureus. 2022;14(9):e28930. · DOI
  61. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015;385(9965):331–40. · DOI · Paper page
  62. Pirillo A, Catapano AL, Norata GD. Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9 and ANGPTL3 inhibitors. Curr Atheroscler Rep. 2021;23:1–8. · DOI
  63. AlHajri L, AlHadhrami A, AlMheiri S, AlMutawa Y, AlHashimi Z. The efficacy of evolocumab in the management of hyperlipidemia: a systematic review. Ther Adv Cardiovasc Dis. 2017;11(5–6):155–69. · DOI
  64. New Medical Devices. P & T : a peer-reviewed journal for formulary management. 2015;40(10):622–697.
  65. Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 2021;6(2):139–47. · DOI
  66. Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial. JAMA Cardiol. 2020;5(8):952–7. · DOI
  67. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941–50. · DOI · Paper page
  68. Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 Inhibitor, in the treatment of dyslipidemia. J Clin Med. 2022;12(1):168. · DOI
  69. Warden BA, Duell PB. Evinacumab for treatment of familial hypercholesterolemia. Expert Rev Cardiovasc Ther. 2021;19(8):739–51. · DOI
  70. Mohamed F, Mansfield B, Raal FJ. Targeting PCSK9 and beyond for the management of low-density lipoprotein cholesterol. J Clin Med. 2023;12(15):5082. · DOI
  71. Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs. 2022;14(1):2014296. · DOI
  72. Wiegman A, Greber-Platzer S, Ali S, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343–53. · DOI
  73. Khoury E, Croteau L, Lauzière A, Gaudet D. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia. Fut Cardiol. 2022;18(6):507–18. · DOI
  74. Raal FJ, Rosenson RS, Reeskamp LF, et al. The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia. JACC: Adv. 2023;2(9):100648.
  75. Li J-J. Tafolecimab, a novel member of PCSK9 monoclonal antibodies, is worth expecting in a Chinese population. JACC Asia. 2023;3(4):646. · DOI
  76. Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410. · DOI
  77. Huo Y, Chen B, Lian Q, et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. The Lancet regional health Western Pacific. 2023;41:100907. · DOI
  78. Chai M, He Y, Zhao W, et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(1):77. · DOI
  79. Keam SJ. Tafolecimab: first approval. Drugs. 2023;83(16):1545–1549. · DOI
  80. Baker DE. Teplizumab. Hos Pharm. 2023;58(6):549–556. · DOI
  81. Menon AP, Moreno B, Meraviglia-Crivelli D, et al. Modulating T cell responses by targeting CD3. Cancers. 2023;15(4):1189. · DOI
  82. Reichert JM: Antibody-based therapeutics to watch in 2011. MAbs. 2011;3(1):76–99. · DOI
  83. Nourelden AZ, Elshanbary AA, El-Sherif L, et al. Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: a systematic review and meta-analysis. Endocr, Metab Immune Disord-Drug Targets (Formerly Curr Drug Targets-Immune, Endocr Metab Disord). 2021;21(10):1895–904. · DOI
  84. Liu Y, Li W, Chen Y, Wang X. Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2024;83(2):322–329. · DOI
  85. Miller SA, St. Onge E. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus. Exp Opin Biol Ther. 2011;11(11):1525–32. · DOI
  86. Jiang Q, Zhang L, Wang R, et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood. 2008;112(7):2858–2868. · DOI
  87. Aronson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37(10):2746–54. · DOI
  88. Singh S, Aggarwal P, Sharma S, Ravichandiran V. Microorganisms in pathogenesis and management of ulcerative colitis (UC). In: role of microorganisms in pathogenesis and management of autoimmune diseases: volume II: kidney, central nervous system, eye, blood, blood vessels & bowel. Springer; 2023;241–253. · DOI
  89. Hale G, Rebello P, Al Bakir I, et al. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol. 2010;50(11):1238–48. · DOI
  90. Wiczling P, Rosenzweig M, Vaickus L, Jusko WJ. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol. 2010;50(5):494–506. · DOI
  91. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003;3(2):123–32. · DOI
  92. Naushad N, Perdigoto AL, Rui J, Herold KC. Have we pushed the needle for treatment of Type 1 diabetes? Curr Opin Immunol. 2017;49:44–50. · DOI
  93. Handa M, Aparnasai RG, Panicker N, Singh S, Ruwali M. Recent trends of extracellular vesicles for therapeutic intervention of brain-related diseases. In: nanomedical drug delivery for neurodegenerative diseases. Elsevier; 2022;119–128. · DOI
  94. Guglielmi C, Williams SR, Del Toro R, Pozzilli P. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opin Biol Ther. 2016;16(6):841–6. · DOI
  95. Geiler J, McDermott MF. Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010;12(6):755–69.
  96. Pafili K, Papanas N, Maltezos E. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases? Expert Opin Investig Drugs. 2014;23(9):1277–84. · DOI
  97. Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. In: 2011: Taylor & Francis. 49–60. · DOI
  98. Eguchi K, Manabe I. Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes Metab. 2013;15(s3):152–8. · DOI
  99. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35(8):1654–62. · DOI
  100. Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022;20(1):1–13. · DOI
  101. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49(2):394–8. · DOI
  102. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20(4):573–91. · DOI · Paper page
  103. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016;133(2):187–225. · DOI · Paper page
  104. Singh S, Aggarwal P, Ravichandiran V. Immunological response of the respiratory tract in the SARS-CoV-2 infection. Coronaviruses. 2021;2(9):8–17. · DOI
  105. Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension. 2022;79(6):1153–66. · DOI
  106. Sinatra ST, Teter BB, Bowden J, Houston MC, Martinez-Gonzalez MA. The saturated fat, cholesterol, and statin controversy a commentary. J Am Coll Nutr. 2014;33(1):79–88. · DOI
  107. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol: WJG. 2009;15(37):4653. · DOI
  108. Gogesch P, Dudek S, van Zandbergen G, Waibler Z, Anzaghe M. The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies. Int J Mol Sci. 2021;22(16):8947. · DOI
  109. Yan S, Zhao X, Xie Q, et al: Pharmacokinetic/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: results from phase I, II, and III studies. Clin Transl Sci. 2023;16(12):2791–2803. · DOI
  110. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(D1):D1091–7. · DOI
  111. Wang EQ, Plotka A, Salageanu J, Sattler C, Yunis C. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK 9, after single subcutaneous injection at three sites [NCT 02043301]. Cardiovasc Ther. 2017;35(5):e12278. · DOI
  112. Chen R, Tian Z, Tang X, Hu P, Wang L, Xia Y, et al. The safety, pharmacokinetics, pharmacodynamics and immunogenicity of ebronucimab in healthy volunteers: result from a phase I, randomized, double-blind, placebo-controlled, single dose-escalation study. Circulation. 2022;146(Suppl_1):A9318-A. · DOI
  113. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discovery. 2010;9(4):325–38. · DOI
  114. Zider A, Drakeman D. The future of monoclonal antibody technology. In: 2010: Taylor & Francis: 361–364. · DOI
  115. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17(20):6389–97. · DOI
  116. Steinwand M, Droste P, Frenzel A, Hust M, Dübel S, Schirrmann T. The influence of antibody fragment format on phage display based affinity maturation of IgG. In: 2014: Taylor & Francis: 204–218. · DOI

Cited by

Sorted by citations

See all 11

Metadata

Authors
Jamadade, P., Nupur, N., Maharana, K. C., & Singh, S.
Venue
Current Atherosclerosis Reports
Publisher
Springer Science and Business Media LLC
Published
2024-07-15
Volume
26
Issue
10
Pages
549-571
ISSN
  • 1523-3804
  • 1534-6242
DOI
10.1007/s11883-024-01228-0
Cited by
11
References
10
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review